Information Provided By:
Fly News Breaks for September 11, 2019
Sep 11, 2019 | 08:38 EDT
William Blair analyst Matt Larew downgraded DaVita to Market Perform from Outperform saying slowing patient growth and ongoing policy and regulatory overhangs "make this a less attractive growth story than in years past." Further, management indicated that it will still take "about three quarters, four quarters" to improve non-acquired growth back to above-industry levels and that its enthusiasm for deals outside of kidney care has waned, Larew tells investors in a research note following the company's capital markets day. As a result, DaVita's sales growth profile, even excluding calcimimetics, is likely to remain "muted," contends the analyst.
News For DVA From the Last 2 Days
There are no results for your query DVA